
teva share close today follow morn
earn call releas guidanc well
consensu expect believ ceo kare schultz may set low
bar year still deeper trough year think
manag cost save plan partial mitig troubl
teva face especi certain intern market japan
russia mexico think teva focu grow newer brand
product ajovi austedo could drive upsid co long-term
neither two product abl fill gap teva
record signific goodwil intang impair due
declin valu busi intern market
anoth impair tie japan lower
revenu estim ep
ebitda forecast maintain
neutral rate teva share
teva target revenu
oper incom ebitda adj ep
 figur well previou
estim think ceo kare schultz may set low
bar dont expect quick recoveri occur co
ww copaxon sale expect drop
yoy drop us proair hfa sale also expect fall due
intro gener albuterol posit note teva expect
ajovi gener sale austedo reach sale
debt repay remain key focu co finish
net debt balanc paid juli
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
teva share close today follow morn earn call releas guidanc
well consensu expect believ ceo kare schultz may set low bar
year still deeper trough year think manag cost save plan
partial mitig troubl teva face especi certain intern market japan russia
mexico think teva focu grow newer brand product ajovi austedo could drive
upsid co long-term neither two product abl fill gap teva
record signific goodwil intang impair due declin valu busi
intern market anoth impair tie japan lower revenu
estim ep ebitda forecast
maintain neutral rate teva share
teva target revenu oper incom ebitda
 adj ep figur well previou estim
think ceo kare schultz may set low bar dont expect quick recoveri occur co
tabl includ teva financi guidanc detail estim
ww copaxon sale expect drop yoy drop us copaxon
treatment relapsing-remit ms quarterli sale miss us estimate vs
estimate morn call manag highlight expect us copaxon sale drop
tie volum declin tie lower price current two gener version
copaxon us market buy pt sandoz novarti nv rate
global copaxon revenu quarter
posit note teva expect austedo deutetrabenazin treatment chorea associ
huntington diseas reach sale estimate sale potenti
averag monthli austedo volum increas vs
 novarti aimovig migrain headach prescript leader cgrp
pack weekli volum teva ajovi lilli emgal recent launch
teva ajovi gain fda approv prevent episod chronic migrain last septemb
eli lilli rate emgal galcenezumab follow suit three approv cgrp-antagonist
drug prevent migrain headach aimovig launch ramp nice sale report
recent cite earn call see increas number paid
prescript paid patient start us cgrp-antagonist sinc launch
sinc introduct aimovig prescript volum ramp new total prescript
dispens decemb accord symphoni health ajovi current posit behind aimovig
weekli volum still earli launch believ new class cgrp-antagonist migrain
treatment like steadili gain traction believ migrain suffer us could
elig seek treatment forecast ajovi sale respect
current maintain forecast gross-to-net discount rang
teva report revenu vs estimate adj gross profit margin basi
point higher forecast howev higher oper expens primarili associ launch
ajovi vs estimate higher contribut lower adj ep vs
estimate result includ lower expect american copaxon sale vs
estimate lower
ltd teva earn model gross oper expens pre-tax adj incom net average share adj analysisgross analysistot earn per co report btig
btig cover compani mention report
appendix analyst certif import disclosur
